更昔洛韦与匹多莫德联合治疗手足口病临床疗效观察

Clinical Curative Effect to Cure Hand-foot-mouth Disease by Therapeutic Alliance of Ganciclovir and Pidotimod

目的:观察更昔洛韦、匹多莫德联合治疗手足口病的临床疗效。方法:将281例手足口病患儿随机分为治疗组和对照组。治疗组150例,给予静点更昔洛韦5mg.kg-1.次-1,1-2次/d,同时应用匹多莫德口服:<2岁,一次0.2g,2次/d;>2岁,一次0.4g,2次/d。对照组131例,给予静点病毒唑15mg.kg-1.d-1。观察临床症状、体征变化进行分析。结果:治疗组总有效率95.34%,对照组总有效率67.18%,两组经统计学分析差异有统计学意义(P<0.05)。结论:更昔洛韦、匹多莫德联合治疗手足口病疗效显著,可明显改善患儿的临床症状、体征,值得推广。

Objective： To observe the clinical curative effect of curing handfootmouth disease by therapeutic alliance of ganciclovir and pidotimod. Method： 281 children with handfootmouth disease were divided into therapy group and control group. In therapy group （ 150 cases） , gave ganciclovir 5mg/kg iv gtt once, 12 times per day, at the same time, gave pidotimod O. 2g once on children younger than 2 years old and twice per day, and gave pidotimod 0.4g once on children older than 2 years old and twice per day. In control group （31 cases） , gave ribovirin lSmg/kg iv gtt per day. Symptoms and signs of two groups. Re sult： Total effective rate was 95.34% in therapy group and 67.18% in control group. There＇s statistic sig nificance the difference in two groups （ P〈0.05 ）. Conclusion： The clinical curative effect for handfoot mouth disease by therapeutic alliance of ganeiclovir and pidotimod is obvious, it can improve symptoms and signs obviously and is worth generalization.